OCC Trading, page-1317

Cannabis? Please, this is not serious stuff. Typical of the rubbish peddled by bogan fund managers when they take a break from tech, mining and banks to tackle biotechs.
A Nasdaq listing makes sense because OCC has FDA approval for Celgro AND a deal with Nasdaq listed Henry Schein. It's that simple.
The main problem with a dual listing is that ASX shareholders will constantly drag down the valuation of the US stock because of the extremely low volume and lack of educated and sophisticated investors in Australia.
A delisting from the ASX and a unique listing in the US on Nasdaq, Russell or NYSE allows the company to be valued on its own merits, and to focus on the real money, the US. Send Paul on a US IPO roadshow. That would be exciting.